Ed Arce
Stock Analyst at WestPark Capital
(3.70)
# 181
Out of 5,182 analysts
363
Total ratings
47.71%
Success rate
48.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $13.26 | +111.24% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $40.81 | -26.49% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.59 | +8,201.89% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $7.23 | +937.34% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $8.30 | +622.89% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.42 | +428.17% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.13 | +153.41% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.37 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.74 | +711.91% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $6.43 | +988.65% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $27.52 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $2.03 | +11,722.66% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.21 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $8.12 | +294.09% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $92.48 | -22.15% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $520.09 | -22.13% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.99 | -8.18% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $23.99 | +296.00% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.28 | +16.82% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $30.45 | +57.64% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $52.95 | -85.84% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $16.37 | -20.59% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $37.28 | -32.94% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.62 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.12 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $32.99 | -78.78% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $32.78 | -35.94% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.36 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $13.26
Upside: +111.24%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $40.81
Upside: -26.49%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.59
Upside: +8,201.89%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $7.23
Upside: +937.34%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $8.30
Upside: +622.89%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.42
Upside: +428.17%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.13
Upside: +153.41%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.37
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.74
Upside: +711.91%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $6.43
Upside: +988.65%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $27.52
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $2.03
Upside: +11,722.66%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $8.12
Upside: +294.09%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $92.48
Upside: -22.15%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $520.09
Upside: -22.13%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.99
Upside: -8.18%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $23.99
Upside: +296.00%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.28
Upside: +16.82%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $30.45
Upside: +57.64%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $52.95
Upside: -85.84%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $16.37
Upside: -20.59%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $37.28
Upside: -32.94%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.62
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $22.12
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $32.99
Upside: -78.78%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $32.78
Upside: -35.94%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $5.36
Upside: -